Publications

At the Texas Liver Tumor Center, our team is known for providing world-class, cutting-edge care. Our experienced hepatologists and surgeons have contributed to many significant publications in the research and understanding of liver tumors and cancers.

Gregory A. Abrahamian, MD

Abstract

  1. Paez AM, Kamath S, Casiraghi F, Davalli AM, Abrahamian G, Ricotti A, La Rosa S, Comuzzie A, Marando A, Finzi G, Dick E, De Fronzo R, Halff G, Folli F. Chronic exenatide infusion increases insulin sensitivity, decreases insulin secretion and stimulates Islet Cell Proliferation in partially Pancreatectomized Baboons 2012. (Diabetologia; vol. 55).
  2. Kamath S, Chavez AO, Casiraghi F, Cline G, Davalli A, Halff G, Abrahamian G, Bastarrachea R, Comuzzie A, Gastaldelli A., Federici M, Marzano V, Urbani A, De Fronzo RA, Folli, F. Critical role of triglycerides and long chain fatty acyl Coa accumulation in liver insulin resistance in the baboon. a new non-human primate model of NAFLD 2011. p. 499-499. (Journal of Hepatology; vol. 54).
  3. Casiraghi F, Chavez AO, Davalli A, Abrahamian GA, Gastaldelli A, Bastarrachea R,Kamath S, Petz R, Zou P,Higgins P,Chang Z, Comuzzie A, Halff G, RALPH DeFronzo RA, Folli F. Effect of Continuous Exenatide Infusion on Insulin Action and Secretion in Partially Pancreatectomized Baboons 2011 Jan. (Diabetes; vol. Supp, no. 1).
  4. Washburn WK, Speeg KV, Guerrero JA, Havranek R, Esterl RM, Abrahamian GA, Cigarroa FG, Halff GA. MELD: Impact of Hepatocellular Carcinoma on the Adult Liver Transplant Waiting List 2003. p. 374A. (Hepatology; vol. 38).
  5. Pollack MS, Speeg KV, Nolan III CR, Washburn WK, Esterl RM, Abrahamian GA, Halff GA. Successful Combined Liver/Kidney Transplantation in Highly Sensitized, Crossmatch Positive Patients. 2002 Oct. p. S74. (Human Immunology; vol. 63, no. 10).

Book Chapter

  1. Jay CL, Abrahamian GA, Edwards AR,. Care of the Pancreas Transplant Recipient (in press) In: Irwin and Rippes Intensive Care Medicine, 8th Edition (in press). Lippincott Williams & Wilkins Health; 2015.
  2. Abrahamian GA. Care of the Pancreas Transplant Recipient In: Irwin RS, Rippe JM. Intensive Care Medicine. Philadelphia: Lippincott; 2012.
  3. Abrahamian GA. Diagnosis and Treatment of Variceal Hemorrhage due to Cirrhosis. In: Esterl RM Speeg KV Abrahamian GA. Acute Care Surgery and Trauma: Evidenced Based Practice. UK: Informa Healthcare, UK, Ltd.; 2009. p. 406 - 414.
  4. Abrahamian GA, Esterl RM. Renal Transplantation. In: Essential Emergency Medicine for the Healthcare Practitioner. Philadelphia, PA: Saunders; 2007.
  5. Abrahamian GA, Cosimi,A.B.. Antithymocyte globulin and monoclonal antibodies. In: Morris,P.j.(ed):Kidney Transplantation, 5th edition. Philadelphia: W.B. Saunders; 2001.

Journal Article

  1. Jay C, Pugh J, Halff G, Abrahamian G, Cigarroa F, Washburn K.. Graft quality matters: Survival after simultaneous liver-kidney transplant according to KDPI Clinical Transplantation 2017 Mar.
  2. Fiorentino TV, Owston M, Abrahamian G, La Rosa S, Marando A, Perego C, Di Cairano ES, Finzi G, Capella C, Sessa F, Casirahi F, Paez An, Adivi A, Davalli A, Fiorina P, Mendoza RG, Comuzzie AG, DeFronzo RA, Halff G, Dick EJ, Folli F. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates (Baboons: Papio Hamadryas) Am J Pathology 2015 Jan;185:139-150.
  3. Tuder D, Pederson WC, Abrahamian GA, Ingari JV, Bagg MC, Person DW, Martyak GG. San Antonio military and civilian hand transplantation program: a case report. Transplant Proc 2011 Nov;43(9):3561-3562.
  4. Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, Defronzo RA, Dick EJ, Cline GW, Folli F. Coordinated defects in hepatic long chain Fatty Acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One 2011 Nov;6(11):27617-27617.
  5. Casiraghi F, Chavez AO, Davalli AM, Abrahamian GA, Gastaldelli A, Bastarrachea RA, Kamath S, Petz R, Zuo P, Ricotti A, Higgins PB, Comuzzie A, Halff GA, DeFronzo RA, Folli F.. Continuous exenatide infusion markedly improves insulin sensitivity and disposition index in partially pancreatectomised baboons Diabetologia 2011;54:S213-S214.
  6. Folli F, Casiraghi F, Davalli AM, Kamath S, Ricotti A, Chang Z, Gastaldelli A, Abrahamian GA, Halff GA, Defronzo RA, Chavez AO. Insulin sensitivity, beta cell function and subclinical inflammation in the baboon, a non human primate model of insulin resistance, obesity and type 2 diabetes. Diabetologia 2011;54(Suppl):S272-S273.
  7. Nadazdin O, Abrahamian G, Boskovic S, Smith RN, Schoenfeld DA, Madsen JC, Colvin RB, Sachs DH, Cosimi AB, Kawai T, Abrahamian GA. Stem Cell Mobilization and Collection for Induction of Mixed Chimerism and Renal Allograft Tolerance in Cynomolgus Monkeys. J Surg Res 2010 Mar.
  8. Cornejo A, Bohnenblust M, Harris C, Abrahamian GA. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation. Cancer Chemother Pharmacol 2009 Sep;64(4):857-860.
  9. Sharron JA, Esterl RM, Washburn WK, Abrahamian GA. Surgical Treatment of an Extrarenal Pseudoaneurysm After Kidney Transplantation. Vasc Endovascular Surg 2009 Feb
  10. Sogawa H, Boskovic S, Nadazdin O, Abrahamian G, Colvin ROBERT, Sachs DAVID, Cosimi A, Kawai T, Abrahamian GA. Limited Efficacy and Unacceptable Toxicity of Cyclophosphamide for the Induction of Mixed Chimerism and Renal Allograft Tolerance in Cynomolgus Monkeys. Transplantation 2008 Aug;86(4):615-619.
  11. Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA. Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol 2005 Jan;66(1):28-31.
  12. Kawai, T., Sogawa, H., Boskovic, S., Abrahamian GA, Smith, R.N., Wee, S.L., Andrews, D., Nadazdin, O., Koyama, I., Sykes, M., Winn, H.J., Colvin, R.B., Sachs, D.H., Cosimi, A.B.. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. American Journal of Transplantation 2004 Sep;4(0):1391-1398.
  13. Jones WT, Ratner I, Abrahamian G, Washburn WK, Esterl R, Neigut D, Halff G. Use of a SILASTIC Silo for Closure of the Abdominal Wall in a Pediatric Patient Receiving a Cadaveric Split Liver. J Pediatric Surgery 2003 Oct;38(10):E20-22.
  14. Halff G, Speeg KV, Washburn K, Esterl R, Abrahamian G, Mejia A, Nichols L, Neigut D, Dodd G, Cigarroa F, Abrahamian GA. Liver transplantation at the University of Texas Health Science Center/University Hospital in San Antonio. Clin Transpl 2003 Jan:247-253.
  15. Bingener-Casey J, Esterl RM, Kenneth Washburn W, Cigarroa FG, Abrahamian GA, Halff GA. Tc-99m-labeled Red Blood Cell Scanning Localizes Anastomotic Hemorrhage Between the Distal Ileum and Duodenal Stump of an Enteric-drained Pancreas Transplant. Clin Nucl Med 2002 Mar;27(3):205-206.
  16. Kawai,T., Cosimi,A.B., Wee,S.L., Houser,S., Andrew,D., Sogawa,H., Phelan,J., Boskovic,S., Nadazdin,O., Abrahamian GA, Colvin,R.B., Sach,D.H., Madsen,J.C.. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 2002 Jan;73(11):1757-1764.
  17. Sogawa,H., Kawai,T., Wee,S.L., Boskovic,S., Nadazdin,O., Phelan,J., Abrahamian GA, Ko, D.S., Hong,H., Mauiyyedi,S., Colvin,R.B., Sachs,D.H.,Cosimi,A.B.,. Comparison of horse antithymocyte globulin with other T cell-depleting antibodies for induction of chimerism and renal allograft tolerance in non-human primates Transplant Proc 2001 Jan;33(1-2):116-117.
  18. Kawai,T., Abrahamian GA, Sogawa,H., Wee,S., Boskovic,S., Andrew,D., Nadazdin,O., Mauiyyedi,S., Weymouth,D., Ko,D., Colvin,R., Sach,D.H., Madsen,J.C.. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates Transplant Proc 2001 Jan;31(1-2):221-222.
  19. Abrahamian GA, Cosimi AB, Farrell ML, Schoenfeld DA, Chung RT, Pascual M. Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transpl 2000 Mar;6(2):185-190.
  20. Kawai,T., Wee,S.L., Bazin,H., Latinne,D., Phelan,J., Boskovic,S., Ko,D.S., Hong,H.Z., Mauiyyedi,S., Nadazdin,O., Abrahamian GA, Preffer,F., Colvin,R.B., Sachs,D.H., Cosimi,A.B.. Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in non-human primates. Transplantation 2000 Jan;70(2):368-374.
  21. Kawai, T., Poncelet, A., Sachs, D.H., Mauiyyedi, S., Boskovic, S., Wee, S.L., Ko, D.S., Bartholomew, A., Kimikawa, M., Hong, H.Z., Abrahamian GA, Colvin, R. B., Cosimi, A.B.. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999;68:1767-1775.
  22. Abrahamian,G.A.,Polhamus,C.,Muskat,P.,Karulf,R.,. Diaphragm-like strictures of the ileum associated with NSAID use: a rare complication. South Medical Journal 1998;91:395-397.
  23. Shikora,S.A.,Abrahamian,G.A.,Gaines,C.E.. Can a bariatric surgery program succeed without close patient proximity? The experience in a military center. Obesity Surgery 1994;4:238-243.

Naim Alkhouri, MD

  1. Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. J Clin Gastroenterol. 2017 Sep 28. [Epub ahead of print].
  2. Alkhouri N, Lawitz E, Poordad F. Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol. 2017 Nov 6;37:107-111. doi: 10.1016/j.coph.2017.10.001. [Epub ahead of print].
  3. Doycheva I, Watt KD, Alkhouri N. Nonalcoholic Fatty Liver Disease in Adolescents and Young Adults: The Next Frontier in the Epidemic. Hepatology. 2017 Jun;65(6):2100-2109.
  4. Issa D, Alkhouri N. Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history. Hepatobiliary Surg Nutr. 2017;6(6):401-403. doi: 10.21037/hbsn.2017.07.07
  5. Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients. J Clin Gastroenterol. 2018 Mar;52(3):268-272. doi: 10.1097/MCG.0000000000000905.
  6. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017. Apr;112(4):581-587.
  7. Alkhouri N. Putting it all Together: Noninvasive Diagnosis of Fibrosis in NAFLD. Clin Liver Dis. 2017. 9 ( 6 ); 134 - 137. DOI:10.1002/cld.636.
  8. Doycheva I, Watt KD, Rifai G, Abou Mrad R, Lopez R, Zein NN, Carey WD, Alkhouri N. Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Dig Dis Sci. 2017 May;62(5):1373-1380. doi: 10.1007/s10620-017-4492-3.
  9. Alkhouri N, Feldstein AE. Treating Nonalcoholic Steatohepatitis (NASH) in Children: Not a Cinch Task. Hepatology. 2017 Apr; 65(4):1407-1409.
  10. Alkhouri N, Zein NN. Three-dimensional printing and pediatric liver disease. Curr Opin Pediatr. 2016 Jun 20. [Epub ahead of print].

Francisco G. Cigarroa, MD

Abstract

  1. Washburn WK, Speeg KV, Guerrero JA, Havranek R, Esterl RM, Abrahamian GA, Cigarroa FG, Halff GA. MELD: Impact of Hepatocellular Carcinoma on the Adult Liver Transplant Waiting List 2003. p. 374A. (Hepatology; vol. 38).
  2. Pollack MS, Havranek, R, Halff GA, Esterl RM, Washburn WK, Cigarroa FG, Speeg KV. Liver Transplant Recipients with Positive T-cell Cross-matches Have Excess Mortality. 2000 Oct. p. s91-s91. (Human Immunology; vol. 61, no. Sup 2).
  3. Elshihabi I, Agustin J, Cigarroa FG, Arar MY. Combined liver-kidney transplantation in a child with primary hyperoxaluria type I. 1998. p. 67. (Pediatr Transplantation; vol. 2, no. sup 1).

Book Chapter

  1. Neigut D, Cigarroa FG:. Biliary atresia. In Mattei P (editor): Surgical Directives: Pediatric Surgery. In: Biliary atresia. Lippincott Williams & Wilkins; 2003. p. Sect X.
  2. Raheb J, Esterl RM, Washburn WK, Cigarroa FG, Halff GA. Ischemic Monomelic Neuropathy as a Complication of Forearm PTFE Loop Grafts in Uremic Diabetic Patients. In: Henry ML, Ed. Vascular Access for Hemodialysis VII. WL Gore and Access Medical Group, Ltd.; 2001. p. 001 - 002.
  3. Raheb J, Esterl RM, Washburn WK, Cigarroa FG, Halff GA. A Revisited Technique to Salvage Failed End to Side Radiocephalic Fistulae for Chronic Hemodialysis. In: Henry ML, Ed. Vascular Access for Hemodialysis VII. WL Gore and Access Medical Group, Ltd.; 2001. p. 01 - 02.
  4. Cigarroa FG. Liver Transplantation in the Managemnt of Patients with Bilary Diseases In: In: La Benge JM(Editor in Chief). The Radiological Society of North America. 1995. p. 118 - 128.
  5. Cigarroa FG. The Harriet Lane Handbook In: In Johnson KB. The Harriet Lane Handbook. 1993. p. 3 - 11.
  6. Cigarroa FG Donahoe PK. Laryngotracheoesphageal Clefts In: Grans SL (Editor) WB Saunders Company. Tracheal Reconstruction in Infancy. 1991. p. 65 - 78.
  7. Cigarroa FG Fritze, Danielle. Cholesdistal Cysts: Hepatic-Pancratico-Biliary and Transplant Surgery In: In Press. Practical assignments of Dilemmas.

Editorial

  1. Cigarroa FG, Jay CL. Disparties in living Donor Kidney Transplantation: Related to Poverty, Race, or Ethnicity? Journal of the American Medical Assoication 2018 Jan;319(1):24-26.
  2. Cigarroa FG. Journal of the American Medical Association Journal of the American Medical Association.

Journal Article

  1. Cigarroa FG. The Beauty of Medicine in UT Health Science Center Ethics Connective Tissue 2013;Vol V(1-6).
  2. Cigarroa F. The UT System: Leadership for reform and rejuvenation of Texas Health Care Texas Heart Institute Journal 2010;37(6):665-666.
  3. Cigarroa FG. The University of Texas System: Leadership for Reform and Rejuvenation of Texas Health Care in Texas Heart Institute Journal 2010;37(6).
  4. Ramirez, AG; Vela, L; Cigarroa, FG. A Model for Health Professional Education in South Texas Journal of Hispanic Higher Education 2008 Apr;Vol 7(2):183-194.
  5. Cigarroa FG. Responding to a Culture-Based Health Need Journal of the American College of Dentists 2008;75(4):8-10.
  6. Cigarroa FG. Liver Transplantation at The University of Texas Health Science Center/University Hospital in San Antonio Clinical Transplants 2004:247-253.
  7.  Washburn WK, Dodd GD III, Kohlmeier RE, McCoy VA, Napier DH, Hubbard LG, Halff GA, Esterl RM, Cigarroa FG, Sharkey FE. Radiofrequency tissue ablation: effect of hepatic blood flow occlusion on thermal injuries produced in cirrhoitic livers. Ann Surg Oncol 2003 Aug;10(7):773-777.
  8. Cigarroa FG. Radiofrequency tissue ablation : effect of hepatic blood flow occlusion on thermal injuries produced in cirrhotic livers. Ann Surg Oncol 2003 Aug;10(7):773-777.
  9. Fisch SI, Vela L, Wartman SA, Cigarroa FG. Community-based medical education: two campuses, one faculty, one school. Tex Med 2002 Aug;98(8):52-54.
  10. Mejia A, Halff GA, Esterl R, Cigarroa F, Speeg KV, Villarreal R, Washburn K. Outcome of Liver Transplantation in Hispanics versus Non-Hispanics: Is There a Difference? Transplant Proc 2002 Jun;34(4):1236-1238.
  11. Leyendecker JR, Dodd GD, Halff GA, McCoy VA, Napier DH, Hubbard LG, Chintapalli KN, Chopra S, Washburn WK, Esterl RM, Cigarroa FG, Kohlmeier RE, Sharkey FE. Sonographically observed echogenic response during intraoperative radiofrequency ablation of cirrhotic livers: pathologic correlation. AJR Am J Roentgenol 2002 May;178(5):1147-1151.
  12. Cigarroa FG. Sonographically Observed Echogenic Response during Intraoperative Radiofrequency Ablation of Cirrhotic Livers: Pathologic Correlation American Journal of Radiology 2002 May;178(5):1147-1151.
  13. Bingener-Casey J, Esterl RM, Kenneth Washburn W, Cigarroa FG, Abrahamian GA, Halff GA. Tc-99m-labeled Red Blood Cell Scanning Localizes Anastomotic Hemorrhage Between the Distal Ileum and Duodenal Stump of an Enteric-drained Pancreas Transplant. Clin Nucl Med 2002 Mar;27(3):205-206.
  14. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G. Steroid Elimination 24 hours After Liver Transplantation Using Daclizumab, Tacrolimus, and Mycophenolate Mofetil. Transplantation 2001 Nov;72(10):1675-1679.
  15. Cigarroa FG. Steroid elimination 24 hours after Liver Transplantation using daclizumab, tacrolimus, and mycophenolate mofetil Transplantation 2001 Nov;72(10):1675-1679.
  16. Cigarroa FG. Outcome of Liver Transplantation in Hispanics Versus Non-Hispanics: Is there a Difference? Transplantation Proceedings 2001 Feb;34:1236-1238.
  17. Lange RA, Hillis LD, Cigarroa FG, Rapp AH, Keeley EC. Prevalence of coronary artery disease in patients with aortic stenosis with and without angina pectoris. Am J Cardiol 2001;88:1212-1213.
  18. Schwesinger WH, Richards ML, Cigarroa FG, Heim-Hall J. Difficulty swallowing in a young child. Grand Rounds Current Surgery 2000;57(5):446-449.
  19. Cai TH, Esterl RM, Nichols L, Cigarroa F, Speeg KV, Halff GA. Improved Immunosuppression with Combination Tacrolimus (FK506) and Mycophenolic Acid in Orthotopic Liver Transplantation. Transplant Proc 1998 Jun;30(4):1413-1416.
  20. Ratner LE, Cigarroa FG, Bender JS, Magnuson T, Kraus ES. Transplantation of single and paired pediatric kidneys into adult recipients. J Am Coll Surg 1997 Nov;185(5):437-445.
  21. Colombani PM, Cigarroa FG, Schwarz K, Wise B, Maley WE, Klein AS. Liver transplantation in infants younger than 1 year of age. Ann Surg 1996 Jun;223(6):658-662.
  22. Ratner LE, Ciseck LJ, Moore RG, Cigarroa FG, Kaufman HS, Kavoussi LR. Laparoscopic live donor nephrectomy. Transplantation 1995 Nov;60(9):1047-1049.
  23. Eckhardt WF, Patafio O, Cigarroa FG. A retained esophageal stethoscope as a potential cause of small bowel obstruction. Anesth Analg 1992 Feb;74(2):300-302.
  24. Lange RA, Cigarroa FG, Hillis LD, Wells PJ, Kremers MS. Influence of antegrade flow in the infarct artery on the incidence of late potentials in acute myocardial infarction Am J Cardiol 1990;65:554-558.
  25. Cigarroa FG, Coughlin JP, Donahoe PK, White MF, Uitvlugt N, MacLaughlin DT. Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase. Growth Factors 1989;1(2):179-191.
  26. Cigarroa FG, Kim SH, Donahoe PK. Imperforate anus with long but apparent low fistula in females. J Pediatr Surg 1988 Jan;23(1 Pt):42-44.
  27. Cigarroa FG. Leading an Academic Health Center in the 21st Century: A Pediatric Surgeon's Perspective Journal of Pediatric Surgery.

Danielle M. Fritze, MD

Abstract

  1. Fritze DM, Englesbe MJ, Campbell DA. Oral Antibiotics to prevent surgical site infections following colon surgery Department of Surgery, University of Michigan; 2011 Jun. p. 141-153.

Journal Article

  1. Fritze DM, Li JY1, Chai B, Zhang W, Wu X, Zhang C, Xia Z, Patterson C, Mulholland MW.. Ankyrin repeat and SOCS box containing protein 4 (Asb-4)colocalizes with insulin receptor substrate 4 (IRS4) in the hypothalamic neurons and mediates IRS4 degradation. BMC Neurosci 2011 Sep;12(95):1471-2202.

Not Specified

  1. Fritze D,KonermanMA, Weinberg R, Sonnenday C, Sharma P. Incidence of risk assessment for adverse cardiovascular outcomes following liver transplantation: a systematic review Transplantation 2017 Mar.
  2. Fritze D. TNFa causes thrombin-dependent vagal neuron apoptosis in inflammatory bowel disease Journal of Gastrointestinal Surgery 2014 Sep;18(9):1632-1641.
  3. Fritze D, Zhang W, Li JY, Chai B, Mulholland MW. Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease Journal of Gastrointestinal Surgery 2014 Aug;18(8):1495-1406.
  4. Fritze D, Scally CP, Reames BN, Teman NR, Minter RM, Gauger PG. Preserving operative volume in the setting of the 2011 ACGME duty hour regualtions J surgical Education 2014 Jul;71(4):580-586.
  5. Fritze D, Waits SA, Banerjee M, Zhang W, Kubus J, Englesbe MJ, Campbell DA Jr, Hendren S. Developing an argument for bundled interventions to reduce surgical site infection in colorectal surgery Surgery 2014 Apr;155(4):602-606.
  6. Fritze D, Li JY, Chai B, Zhang W, Zhang C Mulholland MW. LGR4 and its Ligands, R-spondin 1 and R-spondin 3, regulate food intake in the hypothalamus of male rats Endocrinology 2014;155(2):429-440.
  7. Fritze D, Hendren S, Banerjee M, Kubus J, CLeary RK, Englesbe MJ, Campbell DA. Antibiotic Choice is independently assoicated with risk of surgical site infection after colectomy: a population-based study Annals of Surgery 2013;257(3):469-475.
  8. Fritze D, Mulholland MW, Hussain H,. Hepatic Cyst Disease Shackelford's Surgery of the Alimentary Tract 2013:1453-1463.
  9. Fritze D, Chai B, Li JY, Zhang W, Xia Z, Mulholland MW. A novel transcript is up-regulated by fasting in the hypothalamus and enhances insulin signaling Journal of neuroendocrinology 2013;25(3):292-301.
  10. Fritze D, Krell RW, Zhang C, Chai B, Li J, Mulholland MW. Modulation of food intake by mTOR signaling in the dorsal motor nucleus of the vagus in male rats: focus on the ghrelin and nesfatin-1 Experimental Physiology 2013 Jan;98(12):1696-1704.
  11. Fritze D, Krell RW, Girotti ME, Campbell DA, Hendren S. Hospital readmissions after colectomy: a population-based study Journal of the American College of Surgeons 2013;217(6):1070 1079.
  12. Fritze D, Mulholland MW, Zhang W. Thrombin and Vagal dysfunction in inflammatory bowel disease. Function and Pathophysiology 2012 Jun:235-246.
  13. Fritze D, Mulholland MW, Zhang W.. Protease-Activated Receptor-2 in the Enteric Nervous System Nova Biomedical 2012 Jun:117-131.
  14. Fritze D, Dimick JB. Acute Cholecystitis Scenarios in Surgery: Decision Making and Operative Technique 2012 Jun:106-112.
  15. Fritze D, Muholland MW. Bleeding Gastric Ulcer Scenarios in Surgery: Decision Making and Operative Technique 2012:72-76.
  16. Fritze D, Xia ZF, Li JY, Chai B, Zhang W, Mulholland MW. Nesfatin-1 inhabits gastric acid secretion via a central vagal mechanism in rats American Journal of physiology 2012;303(5):G570-G577.
  17. Fritze DM, Doherty GM. Surgical management of cervical ltmph nodes in differentiated thyoid cancer Otolaryngologic clinics of North America 2010 Apr;43(2):285-300.
  18. Fritze D, Barrett,. Acute Cholecystitis Scenarios in Surgery: Decision making and Operative Technique 2nd ed.
  19. Fritze D, Cigarroa FG. Management of Choledochal cysts in adults Hepato- pancreato-biliary and transplant surgery: practical management and dilemmas.
  20. Fritze D, Minter RM. Bleeding gastric ulcer.

Juan A. Guerrero, MD

Abstract

  1. Cura M, El-Merhi F, SURI R, Lopera JE, Speeg KV, Guerrero JA, Washburn WK, Halff GA. Transplant free survival (TFS) after Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation with the Viatorr covered-stent. 2010. (Cardiovascular and Interventional Radiological Society of Europe).
  2. Dwivedi S, Berg MW, Eidem M, Speeg KV, Guerrero JA, Nazario H, Patel S. Endoscopic Ultrasound-Guided Pericardiocentesis in a Patient With Disseminated Cryptococcus Infection 2009 Apr. p. S240. (Gastrointestinal Endoscopy; vol. 69, no. 2).
  3. Guerrero JA, Speeg KV. HCV Ab Negative HCV Infection in a Kidney Transplant 2005 Oct. (American Journal of Gastroenterology).
  4. Guerrero JA, Brady III CE. Reduced Volume Lavage Solution vs Sodium Phosphate Tablet Preparations for Colonoscopy 2004 May. (Gastrointestinal Endoscopy).
  5. Guerrero JA, Brady III CE, Dalton J. Reduced Volume vs Standard Lavage Solution for Colonoscopy 2004 May. (Gastrointestinal Endoscopy).
  6. Washburn WK, Speeg KV, Guerrero JA, Havranek R, Esterl RM, Abrahamian GA, Cigarroa FG, Halff GA. MELD: Impact of Hepatocellular Carcinoma on the Adult Liver Transplant Waiting List 2003. p. 374A. (Hepatology; vol. 38).

Glenn A. Halff, MD

Abstract

  1. Halff GA, Mansouri M, Poordad F, Lawitz E, Cigarroa F, Halff G, Lopez R, Alkhouri N. Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young patients: Analysis of the Untied Network for Organ Sharing Database Washington, DC.: 2017 Oct. (. The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)).
  2. Halff G, Amanda r. Munoz, Divya Chakravarthy, Jingjing Gong, Rita Ghosh, Addanki P. Kumar. Pancreatic Cancer: Current Status and Challenges Springer; 2017 Oct. (Current Pharmacology Reports; vol. 1).
  3. Halff GA, Jay C, Pugh J, Abrahamian G, Cigarroa F, Washburn K. Graft quality matters: Survival after simultaneous liver-kidney transplant according to KDPI. 2017 May. (Clinical transplant; vol. 31, no. 5).
  4. Halff GA,Jun Liu, Naoki Akanuma, Chengyang Liu, Ali Naji, Glenn A. Halff, William K. Washburn, Luzhe Sun & Pei Wang. TGF-?1 promotes acinar to ductal metaplasia of human pancreatic acinar cells. 2016 Aug. (Scientific reports; vol. 6, no. 30904).
  5. Halff GA, Washburn KW, Matsuoka L, Pandit U, Kim JE, Almenda J. Mora-Esteves C, Genyk Y, Holland B, Wilson DJ, Sher L, Koneru B. Parikh A. A multicenter study of 30 days complications after deceased donor liver transplatation in the model for end-stage liver disease score era 2015 Sep. (Liver Transplant).
  6. Coronado, R, Kenneth, W, Ong, G, Halff GA, Christy, R. Effect of Decellularized Liver Matrix Proteins on Porcine Hepatocytes in vitro. 2014 Oct. (Biomedical Engineering Society Annual Meeting).
  7. Parikh A, Washburn WK, Matsuoka L, Pandit U, Genyk Y, Almeda JL, Mora-Esteves C, Halff GA, Kim J, Holland B, Wilson D, Sher L, Koneru B. Risk Factors for Number and Severity of Complications Following Deceased Donor Liver Transplantation 2014 Jun. p. 291. (Liver Transplantation; vol. 20).
  8. Halff GA, McDiarmid S, Berquist W, Bucuvalas J, Narkewicz M, Millis J, Martin S, Mittal N, Atkison P, Fecteau A, Langnas A, Freese D, Kerkar N, Gilmour S, Fisher R, D‘Alessandro A, Eason J, Kane R, Alonso E, Tzakis A, Rosenthal P, Heffron T, Schwarz K, Andrews W, Lopez J, Bozorgzadeh A, Lowell J, Karpen S, Humar A, Gonzalez-Peralta R, Mazariegos G, Lavine J, Dunn S, Jonas M, Lobritto S, Telega G, Book L, Horslen S, Tector A, Tuttle- Newhall E.. Long-term linear growth and puberty in pediatric liver transplant recipients. Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL: J Pdiatr; 2013 Nov. p. 1354-1360. (The Journal of Pediatrics; vol. 163, no. 5).
  9. Halff GA, Narkewicz MR1, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W; Studies of Pediatric Liver Transplantation Research Group.. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. 2013 Jul. p. 730-740. (Liver Transplant; vol. 19, no. 7).
  10. Xiaoxin Mu, Shu Lin, Junhua Yang, Chen Chen, Yun Chen, Maryanne C. Herzig, Kenneth Washburn, Glenn A. Halff, Christi A. Walter, Beicheng Sun , Lu-Zhe Sun. TGF-? signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells. 2013 May. (Plos / One).
  11. Coronado, R, Kenneth, W, Ong, J, Halff GA, Christy, R. Decellularized Liver Tissue Based Hydrogel for Repair and Regeneration. 2013 Apr. (Society For Biomaterials).
  12. Halff GA,Vicky L.NgMD, FRCP(C)1Estella M.AlonsoMD, John C.Bucuvalas,MD GeoffCohenPhD, Christine A.LimbersPhD, James W.Varni, PhD, George Mazariegos MD, John Magee MD, Susan V. McDiarmid,MD Ravinder Anand,PhD. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr; 2012 May. p. 820-826. (The Journal of Pediatrics; vol. 160, no. 5).
  13. Mu X, Herzig MC, Washburn WK, Walter CA, Halff GA, Sun L. TGF-ß signaling is frequently downregulated in hepatocellular carcinoma, but is retained for malignant phenotype in some hepatocellular carcinoma cells 2012 Apr. (Abstract #3259, AACR 103rd Annual Meeting, Chicago, IL, March 31 - April 2012).
  14. Paez A.M., Kamath S., Casiraghi F., Davalli A., Abrahamian G.A., Ricotti A., Bastarrachea R., Commuzzie A., Owston M., Andreozzi F., Daniele G., Gaggini M., Fanti P., DeFronzo R., Gastaldelli A., Dick E., Halff G., Folli F.. Chronic exenatide infusion increases insulin sensitivity, decreases insulin secretion and stimulates islet proliferation in partially pancreatectomized non-human primates. 2012. (ADA Meeting).
  15. O’Mahony CA, Harring TR, Nguyen TT, Sussman NL, Washburn WK, Halff GA, Goss JA.. Reconstruction Technique for In Situ Split-Liver Transplantation 2011 Apr. p. 340. (American Journal of Transplantation; vol. 11, no. s2).
  16. Nguyen NTT, Ha CP, Harring TR, Chu D, Kar B, O‘Mahony C, Bakaeen F, Washburn WK, Halff GA, Goss JA, Speeg KV,. Dilated Cardiomyopathy after Orthotopic Liver Transplantation: A Multi-Institution Report of Six Cases Treated with Mechanical Assist Devices 2011 Jan. (Hepatology; vol. 54, no. 661).
  17. Kamath S, Chavez AO, Casiraghi, Cline G, Davalli A, Halff GA, Abrahamian G, Bastarrachea R, Comuzzie A, Gastaldelli A, Federici M, Marzano V, Urbani A, De Fronzo RA, Folli F.. Critical role of triglycerides and long chain fatty acyl Coa accumulation in liver insulin resistance in the baboon, a new non-human primate model of NAFLC 2011 Jan. p. S499-S499. (Journal of Hepatology; vol. 54, no. Suppl).
  18. Casiraghi F, Chavez AO, Davalli A, Abrahamian GA, Gastaldelli A, Bastarrachea R,Kamath S, Petz R, Zou P,Higgins P,Chang Z, Comuzzie A, Halff G, RALPH DeFronzo RA, Folli F. Effect of Continuous Exenatide Infusion on Insulin Action and Secretion in Partially Pancreatectomized Baboons 2011 Jan. (Diabetes; vol. Supp, no. 1).
  19. Lytvak I, Prihoda TJ, Speeg KV, Halff GA, Sharkey FE. Microsteatosis More Sigificant than Macrosteatosis in Predicting Early Post-Transplant Hepatic Non-Function 2010. p. 364A. (Modern Pathology; vol. 23).
  20. Cura M, El-Merhi F, SURI R, Lopera JE, Speeg KV, Guerrero JA, Washburn WK, Halff GA. Transplant free survival (TFS) after Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation with the Viatorr covered-stent. 2010. (Cardiovascular and Interventional Radiological Society of Europe).
  21. Cura M, Speeg KV, El-Merhi F, SURI R, Lopera JE, Washburn WK, Halff GA. Transjugular intrahepatic portosystemic shunts (TIPS) creation in recurrent hepatitis C (HCV) cirrhosis after Liver Transplantation (LT). 2010. (Cardiovascular and Interventional Radiology Society of Europe).
  22. Halff GA,Vicky Lee Ng, Annie Fecteau, Ross Shepherd, John Magee, John Bucuvalas, Estella Alonso, Suzanne McDiarmid, Geoff Cohen, Ravinder Anand. Outcomes of 5-Year Survivors of Pediatric Liver Transplantation: Report on 461 Children From a North American Multicenter Registry 2008 Dec. p. 1128-1135. (Pediatrics; vol. 122, no. 6).
  23. Feng S, Roberts J, Halff G, Washburn K. Factors Influencing Liver Transplant Length Of Stay And Resource Utilization At Two Large Volume Transplant Centers 2007 Sep. p. 234a. (Hepatology; vol. 46, no. s1).
  24. Barshes NR, Washburn WK, Goss JA, Halff GA. Discrepancies In Deceased Donor Liver Allocation Within A Single Unos Region 2006 Aug. p. 785. (American Journal of Transplantation; vol. 6, no. s2).
  25. Mejia A, Barshes NR, Goss JA, Washburn WK, Halff GA. Influence Of Deceased Donor Split Liver Grafts On The Pediatric Recipient’s Growth 2005 Jun. (Liver Transplantation; vol. 11, no. 7).
  26. Washburn WK, Nichols, L, Mejia A, Speeg KV, Halff GA. Recipient MELD Score and Resource Utilization: Higher is Higher. Presented at the American Transplant Congress, Seattle, WA: 2005 May. p. 425. (American Journal of Transplantation; vol. 5, no. s11).
  27. Washburn WK, Harper, A, Klintmalm, G, Goss, J, Halff GA. Regional Sharing for Status 1 Patients:Reduction in Waitlist Mortality. Presented at the American Transplant Congress, Seattle, WA: 2005 May. p. 263. (American Journal of Transplantation; vol. 5, no. s11).
  28. Mejia A, Saad A, Washburn K, Cigarroa F, Halff G. Linear Growth Of Pediatric Split Liver Recipients: Is There A Disadvantage? 2005 May. p. 339. (American Journal of Transplantation; vol. 5, no. s11).
  29. Washburn WK, Halff G., Mieles L., Goldstein R., Goss J.. Split Liver Transplantation: Statewide Usage of the Right Trisegmental Graft. Presented at the American Transplant Congress, Boston, MA: 2004 May. p. 437. (American Journal of Transplantation; vol. 4, no. s8).
  30. Pollack MS, Speeg KV, Callander NS, Freytes CO, Halff GA. Severe graft versus host disease manifesting eight months after liver transplantation 2004. p. S63-S63. (Human Immunology; vol. 65).
  31. Washburn WK, Speeg KV, Guerrero JA, Havranek R, Esterl RM, Abrahamian GA, Cigarroa FG, Halff GA. MELD: Impact of Hepatocellular Carcinoma on the Adult Liver Transplant Waiting List 2003. p. 374A. (Hepatology; vol. 38).
  32. Pollack MS, Speeg KV, Nolan III CR, Washburn WK, Esterl RM, Abrahamian GA, Halff GA. Successful Combined Liver/Kidney Transplantation in Highly Sensitized, Crossmatch Positive Patients. 2002 Oct. p. S74. (Human Immunology; vol. 63, no. 10).
  33. Pollack MS, Havranek, R, Halff GA, Esterl RM, Washburn WK, Cigarroa FG, Speeg KV. Liver Transplant Recipients with Positive T-cell Cross-matches Have Excess Mortality. 2000 Oct. p. s91-s91. (Human Immunology; vol. 61, no. Sup 2).
  34. Salazar RM, Peters JI, Levine SM, Anzueto AR, Susanto I, Maxwell P, Sako EY, Halff GA. Evaluation of renal toxicity of amphotericin B lipid complex (ABLC) in solid organ transplant (SOT) patients 1999 Mar. p. A537. (Am J Respir Crit Care Med; vol. 159, no. 3).
  35. Elshihabi I, Halff GA, Calhoon JH, Kaspar D. Simultaneous heart and kidney transplant in a child 1995 Aug. (10th Congress of the International Pediatric Nephrology Association).
  36. Mohar DE, Bryan CL, Jenkinson SG, Anzueto AR, Peters JI, Levine SM, Halff GA. HLA matching as a predictor of OB or death in SLT 1993 Feb. p. 157S.(Chest; vol. 104, no. 2).

Book Chapter

  1. Espinoza A, Speeg KV, Washburn K, Halff G. Liver Transplantation In: Espinoza A, Speeg, Washburn K, Halff G. Essential Emergency Medicine for the Healthcare Practitioner. Saunders-Elsevier; 2007.
  2. Raheb J, Esterl RM, Washburn WK, Cigarroa FG, Halff GA. Ischemic Monomelic Neuropathy as a Complication of Forearm PTFE Loop Grafts in Uremic Diabetic Patients. In: Henry ML, Ed. Vascular Access for Hemodialysis VII. WL Gore and Access Medical Group, Ltd.; 2001. p. 001 - 002.
  3. Raheb J, Esterl RM, Washburn WK, Cigarroa FG, Halff GA. A Revisited Technique to Salvage Failed End to Side Radiocephalic Fistulae for Chronic Hemodialysis. In: Henry ML, Ed. Vascular Access for Hemodialysis VII. WL Gore and Access Medical Group, Ltd.; 2001. p. 01 - 02.
  4. Speeg VJ Jr, Halff GA, Schenker S. Metabolism of drugs before and after liver transplantation. In: Maddrey WC, Sorrell MF. Transplantation of the Liver, 3rd Edition. Philadelphia, PA: Lippencott, Williams & Wilkins; 2001.
  5. Dodd III GD, Halff GA, Rhim RC, Maldan MA. Thermal Ablation of Hepatic Tumors by Radiofrequency, Microwave, or Laser Therapy In: Blackwell Science Inc. 1999. p. 170 - 180.
  6. Speeg KV, Halff GA, Schenker S. Metabolism of Drugs Before and After Liver Transplantation In: Maddrey, Transplantation of the Liver. New York, NY: Elsevier; 1995.

Journal Article

  1. Halff Glen A Ramon E. Coronado Maria Somaraki-Cormier Shanmugasundaram Natesan Robert J Christy Joo L Ong . Decellularization and Solubilization of Porcine Liver for Use as a Substrate for Porcine Hepatocyte Culture SAGE journals 2018 Feb;26(12):1840-1854.
  2. Parikh A, Washburn KW, Matsuoka L, Pandit U, Kim JE, Almeda J, Mora-Esteves C, Halff G, Genck Y, Holland B, Wilson DJ, Sher L, Koneru B. A multi-center study of 30 days complications after deceased donor liver transplantation in the model for end stage liver disease score era. LIver Transplantation 2015 May;21(9):1160-1168.
  3. Halff GA, Fiorentino TV, Owston M, Abrahamian G, La Rosa S, Marando A, Perego C5, Di Cairano ES, Finzi G, Capella C, Sessa F, Casiraghi F, Paez A, Adivi A, Davalli A, Fiorina P, Guardado Mendoza R11, Comuzzie AG, Sharp M, DeFronzo RA, Dick EJ, Folli F. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. American Journal of Pathology 2015 Jan;185(1):139-150.
  4. Mu X, Lin S, Yang J, Chen C, Herzig MC, Washburn WK, Halff GA, Walter CA, Sun B, Sun L. TGF-ß signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells Plos One 2013 May;8(5):e63436
  5. Paez AM, Kamath S, Casiraghi F, Davalli AM, Abrahamian G, Ricotti A, La Rosa S, Comuzzie A, Marando A, Finzi G, Dick E, De Fronzo R, Halff GA, Folli F.. Chronic exectatide infusion increases insulin sensitivity, decreases insulin secretion and stimulates islet cell proliferation in partially pancreatectomized baboons. Diabetologia 2012;55(Suppl):S291
  6. Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, Defronzo RA, Dick EJ, Cline GW, Folli F. Coordinated defects in hepatic long chain Fatty Acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One 2011 Nov;6(11):27617-27617.
  7. Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA. High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation. Hum Pathol 2011 Sep;42(9):1337-1342.
  8. Halff GA, Washburn K. Hepatocellular carcinoma and liver transplantation curr Opin Organ Transplant 2011 Jun;16(3):297-300.
  9. Martin SR, Alvarez F, Anand R, Song C, Yin W,. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transplant 2011 Apr;17(4):393-401.
  10. Casiraghi F, Chavez AO, Davakku A, Abrahamian GA, Gastaldelli A, Bastarrachea R, Kamath S, Petz R, Zou P, Hibbins P, Chang Z, Comuzzie A, Halff GA, Defronzo RA, Folli F. Effect of continuous exenatide infusion on insulin action and secretion in partially pacreatectomized baboons. Diabetes 2011;(Suppl)
  11. Halff GA, Wang Y, Speeg KV, Washburn WK. Sirolimus Plus Sorafenib in Treating HCC Recurrence after Liver Transplantation: A Case Report World Journal of Gastroenterology 2010 Nov;16(43):5518-5522.
  12. Halff GA, Yubao Wang, Kermit V Speeg, William Kenneth Washburn,. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World Journal of Gastroenterology 2010 Nov;16(43):5518-5522.
  13. Halff GA, Guiteau JJ, Cotton RT, Washburn WK, Harper A, O'Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Mieles l, Goss J.. An Early regional experience with expansion of Milan Criteria for liver transplant recipients American Journal of Transplant 2010 Sep;10(9):2092-8098.
  14. Washburn WK, Meo NA, Halff GA, Roberts JP, Feng S. Factors influencing liver transplant length of stay at two large-volume transplant centers. Liver Transplant 2009 Nov;15(11):1570-1578.
  15. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Perego C, Goldschmidt L, Hart J, Comuzzie AG, Tejero ME, Finzi G, Pacidi C, LaRosa S, Capela C, Halff G, Gastaldelli A, Defronzo RA, Foli F. Pancreatic Islet Amyloidosis, Beta Cell Apoptosis,and Alpha Cell Proliferation are Determinants of Islet Remodeling in Type 2 Diabetic Baboons Proc Natl Acad Sci USA 2009 Aug;106(33):13992-13997.
  16. Washburn W, Meo N, Halff GA, Roberts JP, Feng S. Factors Influencing Liver Transplant Length of Stay at Two Large-Volume Transplant Centers Liver Transplantation 2009;15:1570-1578.
  17. Halff GA, Ng VL, Fecteau A, Shepherd R, Magee J, Bucuvalas J, Alonso E, McDiarmid S, Cohen G. Outcomes of 5-year Survivors of Pediatric Liver Transplantation: Reprt on 461 Children from a North American Multicenter Registry Transplantation Research Group 2008 Dec;122(6):1128-1135.
  18. Barshes NR, Becker NS, Washburn WK, Halff GA, Aloia TA, Goss JA. Geographic disparities in deceased donor liver transplantation within a single UNOS region. Liver Transplant 2007 May;13(5):747-751.
  19. Halff GA, Mejia A, Barshes N, Goss J, Washburn WK. Use of Split-Liver Allografts Does Not Impair Pediatric Recipient Growth Liver Transplantation 2007 Jan;13(1):145-148.
  20. Halff G, Washburn WK, Pollock BH, Nichols L, Speeg KV. Impact of recipient MELD score on resource utilization American Journal Transplant 2006 Oct;6(10):2449-2454.
  21. Lee TC, Barshes NR, Washburn WK, Halff GA, Carter BA, Karpen SJ, Bristow LJ, Scott JD, Goss JA. Split-liver transplantation using the left lateral segment: a collaborative sharing experience between two distant centers. Am J Transplant 2005 Jul;5(7):1646-1651.
  22. Washburn K, Halff G, Mieles L, Goldstein R, Goss JA, Halff GA. Split-liver transplantation: results of statewide usage of the right trisegmental graft. Am J Transplant 2005 Jul;5(7):1652-1659.
  23. Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA. Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol 2005 Jan;66(1):28-31.
  24. Lovell MO, Speeg KV, Halff GA, Molina DK, Sharkey FE. Acute hepatic allograft rejection: a comparison of patients with and without centrilobular alterations during first rejection episode. Liver Transplantation 2004 Mar;10(3):369-373.
  25. Cigarroa FG. Liver Transplantation at The University of Texas Health Science Center/University Hospital in San Antonio Clinical Transplants 2004:247-253.
  26. Jones WT, Ratner I, Abrahamian G, Washburn WK, Esterl R, Neigut D, Halff G. Use of a SILASTIC Silo for Closure of the Abdominal Wall in a Pediatric Patient Receiving a Cadaveric Split Liver. J Pediatric Surgery 2003 Oct;38(10):E20-22.
  27. Nunez A, Goodpastor SE, Goss JA, Washburn WK, Halff GA. Enlargement of the cadaveric-liver donor pool using in-situ split-liver transplantation despite complex hepatic arterial anatomy. Transplantation 2003 Oct;76(7):1134-1136.
  28. Washburn WK, Dodd GD III, Kohlmeier RE, McCoy VA, Napier DH, Hubbard LG, Halff GA, Esterl RM, Cigarroa FG, Sharkey FE. Radiofrequency tissue ablation: effect of hepatic blood flow occlusion on thermal injuries produced in cirrhoitic livers. Ann Surg Oncol 2003 Aug;10(7):773-777.
  29. Cigarroa FG. Radiofrequency tissue ablation : effect of hepatic blood flow occlusion on thermal injuries produced in cirrhotic livers. Ann Surg Oncol 2003 Aug;10(7):773-777.
  30. Mejia A, Halff GA, Esterl R, Cigarroa F, Speeg KV, Villarreal R, Washburn K. Outcome of Liver Transplantation in Hispanics versus Non-Hispanics: Is There a Difference? Transplant Proc 2002 Jun;34(4):1236-1238.
  31. Leyendecker JR, Dodd GD, Halff GA, McCoy VA, Napier DH, Hubbard LG, Chintapalli KN, Chopra S, Washburn WK, Esterl RM, Cigarroa FG, Kohlmeier RE, Sharkey FE. Sonographically observed echogenic response during intraoperative radiofrequency ablation of cirrhotic livers: pathologic correlation. AJR Am J Roentgenol 2002 May;178(5):1147-1151.
  32. Cigarroa FG. Sonographically Observed Echogenic Response during Intraoperative Radiofrequency Ablation of Cirrhotic Livers: Pathologic Correlation American Journal of Radiology 2002 May;178(5):1147-1151.
  33. Bingener-Casey J, Esterl RM, Kenneth Washburn W, Cigarroa FG, Abrahamian GA, Halff GA. Tc-99m-labeled Red Blood Cell Scanning Localizes Anastomotic Hemorrhage Between the Distal Ileum and Duodenal Stump of an Enteric-drained Pancreas Transplant. Clin Nucl Med 2002 Mar;27(3):205-206.
  34. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G. Steroid Elimination 24 hours After Liver Transplantation Using Daclizumab, Tacrolimus, and Mycophenolate Mofetil. Transplantation 2001 Nov;72(10):1675-1679.
  35. Cigarroa FG. Steroid elimination 24 hours after Liver Transplantation using daclizumab, tacrolimus, and mycophenolate mofetil Transplantation 2001 Nov;72(10):1675-1679.
  36. Cigarroa FG. Outcome of Liver Transplantation in Hispanics Versus Non-Hispanics: Is there a Difference? Transplantation Proceedings 2001 Feb;34:1236-1238.
  37. Patterson JE, Peters J, Calhoon JH, Levine S, Anzueto A, Al-Abdely H, Sanchez R, Patterson TF, Rech M, Jorgensen JH, Rinaldi MG, Sako E, Johnson S, Speeg V, Halff GA, Trinkle JK. Investigation and Control of Aspergillosis and Other Filamentous Fungal Infections in Solid Organ Transplant Recipients Transpl Infect Dis 2000 Mar;2(1):22-28.
  38. Sabo B, Dodd III GD, Halff GA, Naples JJ. Anesthetic considerations in patients undergoing percutaneous radiofrequency interstitial tissue ablation. AANA J 1999 Oct;67(5):467-468.
  39. St Laurent M, Esterl RM, Halff GA, Speeg KV. Gallbladder Carcinoma Producing Alpha-fetoprotein. J Clin Gastroenterol 1999 Mar;28(2):155-158.
  40. Rhim R, Dodd III GD, Halff GA. Ultrasound Guided Thermal Ablation of Malignant Hepatic Tumors. Ultrasound Quarterly 1999;15:93-102.
  41. St Laurent M, Surendranath C, Saad T, Halff G, Esterl R. A New Salvage Procedure for Peritoneal Dialysis Catheters with Exit Site Infections. Am Surg 1998 Dec;64(12):1215-1217.
  42. Halff GA. Liver Transplants Becoming Routine San Antonio Medicine 1998 Nov;51(11):16-16.
  43. Cai TH, Esterl RM, Nichols L, Cigarroa F, Speeg KV, Halff GA. Improved Immunosuppression with Combination Tacrolimus (FK506) and Mycophenolic Acid in Orthotopic Liver Transplantation. Transplant Proc 1998 Jun;30(4):1413-1416.
  44. Lahiri SA, Halff GA, Speeg KV, Esterl RM. Indium-111 WBC Scan Localizes Infected Hepatic Cysts and Confirms Their Complete Resection in Adult Polycystic Disease. Clin Nucl Med 1998;23(1):33-34.
  45. Freyaldenhoven S, Halff GA, Esterl RM. Reflux into Redundant Duodenal Stump of Pancreatic Allograft Imitates Duodenal Stump Leak on Tc-99m MAG3 Scintigraphy. Clin Nucl Med 1997 May;22(5):338-339.
  46. Felger J, Halff GA, Esterl RM. Exposure to Mycobacterium tuberculosis (MTB) in a Renal Transplant Candidate: What Further Preoperative Screening Tests are Available? Clin Transplant 1997 Apr;11(2):142-148.
  47. Esterl RM, St Laurent M, Bay MK, Speeg KV, Halff GA. Stent Migration and Small Bowel Perforation After Endoscopic Biliary Stent Placement in a Liver Transplant Recipient. J Clin Gastroenterol 1997 Mar;24(2):106-110.
  48. Stephenson K, Gupta A, Mustafa SB, Halff GA. Endothelin-Stimulated Nitric Oxide Production in the Isolated Kupffer Cell Journal of Surgical Research 1997;73:149-154.
  49. Halff GA, Esterl RM, Speeg KV. The Use of Cellcept to Minimize Prograf Toxicity in Early Post-operative Liver Transplant Patients with Renal Insufficiency. J Hepatology 1996;25:203-203.
  50. Esterl RM, Halff GA. The Use of Methylene Blue in the Identification of Lymphoceles after Renal Transplantation. Urology 1995 Jun;45(6):1088-1089.
  51. Marvin RG, Halff GA, Elshihabi I. Renal allograft torsion associated with prune-belly syndrome. Pediatr Nephrol 1995 Feb;9(1):81-82.
  52. Marvin RG, Halff GA, Elshihabi I. Renal Allograft Torsion Associated with Prune Belly Syndrome Pediatric Nephrology 1995;9(1):81-82.
  53. Stephenson K, Halff GA. Endothelin Stimulates Nitric Oxide Production in the Isolated Rat Kupffer Cell FASEB J 1994;A924
  54. Schenker S, Halff GA. Nutritional therapy in alcoholic liver disease. Semin Liver Dis 1993 May;13(2):196-209.
  55. Schenker S, Halff GA. Nutritional Therapy in Alcoholic Liver Disease Seminars in Liver Disease 1993;13:196-209.
  56. Harris LJ, Crooke GA, Grossi EA, Teperman LW, Halff GA, Galloway AC, Spencer FC, Weil R. Anatomic distribution of preservation solutions during canine hepatic procurement. Transplant Proc 1991 Oct;23(5):2430-2431.
  57. Teperman LW, Baumann FG, Harris L, Crooke G, Halff GA, Weil R. Improved arterial allograft preservation with the University of Wisconsin solution. Transplant Proc 1991 Feb;23(1 Pt):896-898.
  58. Toth A, Abdallah HY, Venkataramanan R, Teperman L, Halff GA, Rabinovith M, Burckhart GJ, Starzl TE. Parmacokinetics of Ceftriaxone in Liver Transplant Recipients Journal of Clinical Pharmacology 1991;8:722-728.
  59. Halff GA, Todo S, Tzakis AG, Gordon RD, Starzl TE. Liver Transplantation for the Budd-Chiari Syndrome Ann Surg 1990;211:43-49.
  60. Teperman L, Halff GA, Tzakis AG. Peritoneovenous Shunting vs. Medical Treatment in Patients with Alcoholic Cirrhosis and Massive Ascites NEJM 1990;322:1750-1750.
  61. Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE, Halff GA. Liver transplantation for the Budd-Chiari syndrome. Ann Surg 1990 Jan;211(1):43-49.
  62. Halff G, Todo S, Hall R, Starzl TE, Halff GA. Late complications with gallbladder conduit biliary reconstruction after liver transplantation. Transplantation 1989 Sep;48(3):537-539.
  63. Halff GA, Todo S, Hall R, Starzl TE. Late Complications with the Gallbladder Conduit Biliary Reconstruction After Liver Transplantation Transplantation 1989;49:537-539.

Not Specified

  1. Halff GA. , "Pancreatic Cancer: Current Status and Challenges" Current Pharmacology Reports

Other

  1. Esterl RM, Washburn WK, Halff GA. UTHSCSA and Liver, Kidney and Pancreas Transplantation. San Antonio Medicine 2005 Feb;58(2):32-33.
  2. Bready LL, Rasch DK, Halff GA, Elshihabi, I, Gamboa, C. Renal Transplantation for the Pediatric Patient In: Clinical Protocols for the UTHSCSA Department of Anesthesiology 1995 Feb
  3. Coppa GF, Halff GA. Prediction of Outcome in Critically Ill Patients Intensive Care and Emergency Med 1992:673-681.

Colleen L. Jay, MD

Editorial

  1. Schold JD, Buccini LD, Phelan MP, Jay CL, Goldfarb DA, Poggio ED, Sedor JR. Building an Ideal Quality Metric for ESRD Healthcare Delivery Clinical Journal of the American Society of Nephrology 2017 May.
  2. Jay CL, Schold JD.. Measuring Transplant Center Performance: The Goals are not Controversial, but the Methods and Consequences can be. Current Transplant Reports 2017 Mar;4(1):52-58.
  3. Jay CL, Skaro AI. Comparative effectiveness research in liver transplantation: crossing the cost and quality chasm. J Comp Eff Res 2013 Jan;2(1):7-9.
  4. Gordon EJ, Daud A, Caicedo JC, Cameron KA, Jay C, Fryer J, Beauvais N, Skaro A, Baker T, Jay CL. Informed consent and decision-making about adultto-adult living donor liver transplantation: a systematic review of empirical research. Transplantation 2011 Dec;92(12):1285-1296.
  5. Skaro AI, Jay CL, Ladner D, Abecassis MM. Trends in donation after cardiac death and donation after brain death--reading between the lines. Am J Transplant 2010 Nov;10(11):2390-2391.

Journal Article

  1. Jay CL, Washburn K, Dean PG, Helmick RA, Pugh JA, Stegall MD. Survival Benefit in Older Patients Associated with Earlier Transplant with High KDPI Kidneys Transplantation 2016 Aug;101(4):867-872.
  2. Jay CL, Dean PG, Helmick RA, Stegall MD. Reassessing Preemptive Kidney Transplantation in the United States: Are we making progress? Transplantation 2016 May;100(5):1120-1127.
  3. Chang Y, Gallon L, Shetty K, Chang Y, Jay C, Levitsky J, Ho B, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI, Jay CL. Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies. Transplantation 2015 Feb;99(2):424-430.
  4. Chang Y., Gallon L., Jay C., Shetty K., Ho B., Levitsky J., Baker T., Ladner D., Friedewald J., Abecassis M., Hazen G., Skaro A.. Comparative Effectiveness of Liver Transplant Strategies for End-stage Liver Disease Patients on Renal Replacement Therapy Liver Transplantation 2014 Sep;20(9):1034-1044.
  5. Jay CL. Skaro AI. Ladner DP. Wang E. Lyuksemburg V. Chang Y. Xu H. Talakokkla S. Parikh N. Holl JL. Hazen GB. Abecassis MM. Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: Recognizing who can benefit Liver Transplantation 2012 Jun;18(6):630-640.
  6. Jay C. Ladner D. Wang E. Lyuksemburg V. Kang R. Chang Y. Feinglass J. Holl JL. Abecassis M. Skaro AI. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry Journal of Hepatology 2011 Oct;55(4):808-813.
  7. Jay CL. Lyuksemburg V. Ladner DP. Wang E. Caicedo JC. Holl JL. Abecassis MM. Skaro AI. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Annals of Surgery 2011 Feb;253(2):259-264.
  8. Baker TB, Jay CL, Fryer JP, Abecassis MM. Transplant renoportal vein conduit for complete mesenteric thrombosis: a case report. Am Surg 2010 Sep;76(9):1016-1019.
  9. Jay CL, Skaro AI, Kang R, Lyuksemburg V, Preczewski L, Stroupe K, Holl JL, Abecassis MM. The increased costs of donation after cardiac death liver transplantation: caveat emptor Annals of Surgery 2010 Apr;251(4):743-748.
  10. Jay CL, Butt Z, Ladner DP, Skaro AI, Abecassis MM. A review of quality of life instruments used in liver transplantation. J Hepatol 2009 Nov;51(5):949-959.
  11. Skaro AI, Jay CL, Baker TB, Wang E, Pasricha S, Lyuksemburg V, Martin JA, Feinglass JM, Preczewski LB, Abecassis MM. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery 2009 Oct;146(4):543-552.
  12. Jay CL, Baker TB, Ladner DP, Preczewski LB, Clark L, Holl JL, Abecassis MM. Laparoscopy-assisted and open living donor right hepatectomy: a comparative study of outcomes Surgery 2009 Oct;146(4).
  13. Sandoval JA, Hoelz DJ, Woodruff HA, Powell RL, Jay CL, Grosfeld JL, Hickeyd RJ, Malkas LH. Novel peptides secreted from human neuroblastoma: useful clinical tools? J Pediatr Surg 2006 Jan;41(1):245-251.
  14. Escobar MA, Jay CL, Brooks RM, West KW, Rescorla FJ, Molleston JP, Grosfeld JL. Effect of corticosteroid therapy on outcomes in biliary atresia after Kasai portoenterostomy. J Pediatr Surg 2006 Jan;41(1):99-103.
  15. Escobar MA, Grosfeld JL, Burdick JJ, Powell RL, Jay CL, Wait AD, West KW, Billmire DF, Scherer LR, Engum SA, Rouse TM, Ladd AP, Rescorla FJ. Surgical considerations in cystic fibrosis: a 32-year evaluation of outcomes. Surgery 2005 Oct;138(4):560-571.

Tarunjeet S. Klair, MD

Publications

  1. T.Klair, A.Gregg, J. Phair, L.Kayler. Outcomes of Adult Dual Kidney Transplants by KDRI in the United States. American of Journal of Transplantation 2013; 13:2433-2440.
  2. M Vivanco, P Friedmann, Y Xia, T Klair, K Marfo, G de Boccardo, S Greenstein, J Chapochnick-Friedmann, M Kinkhabwala, M Ajaimy, ML. Lubetzky, E Akalin, LK Kayler. Campath induction in HCV and HCV/HIV-seropositive kidney transplant recipients. Transplant International Volume 26, Issue 10, 1016–1026, October 2013.
  3. B Samstein , T Klair. Living Donor Liver Transplantation: Donor Selection and Living Donor Hepatectomy. Current Surgery Reports, September 2015, Volume 3, Issue 9.
  4. TS Klair, JV Guarrera. Breaking the Ice: Early Clinical Results Using Hypothermic Machine Liver Preservation. Current Transplantation Reports March 2015, Volume 2, Issue 1, pp 63-67.
  5. TS Klair, JV Guarrera. Machine Perfusion and Innovations in Liver Transplant Preservation. Current Surgery Reports, January 2016, 4:2.

Nicole Ming-Ming Loo, MD

  1. Liver and Spleen Stiffness Measurements by Point Shear Wave Elastography via Acoustic Radiation Force Impulse: Intraobserver and Interobserver Variability and Predictors of Variability in a US Population. Balakrishnan M; Souza F; Munoz C; Augustin S; Loo N; Deng Y; Ciarleglio M; Garcia-Tsao G. J Ultrasound Med. 2016 Nov; 35 (11): 2373-2380.
  2. Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy. Wi CI; Loo NM; Larson JJ; Moynihan TJ; Madde NR; Grendahl DC; Alberts SR; Kim WR. Clin Gastroenterol Hepatol. 2015 May; 13(5):970-5.
  3. Non-hemorrhagic Acute Complications Associated with Cirrhosis and Portal Hypertension. Loo NM; Souza FS; Garcia-Tsao G. Best Prac Res Cl Ga. 2013 Oct; 27(5): 665-678.
  4. Hepatitis B Screening in a US Academic Primary Care Practice. Loo NM; Kim WR; Larson JJ; Wieland M; Chaudhary R. Arch Intern Med. 2012 Oct 22.172(19):1517-9.
  5. Exploring Hepatitis B: a neglected disease. Loo NM; Pryce DJ. Minn Med. 2012 May; 95 (5):37-40.

Fred F. Poordad, MD

  1. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa F. Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print]
  2. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print]
  3. Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR. Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis. J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083-4. doi: 10.1016/j.jhep.2017.06.011. [Epub ahead of print]
  4. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 3;5(4):371-375.
  5. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30211-8. doi: 10.1016/j.jhep.2017.03.039. [Epub ahead of print]
  6. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print]
  7. Poordad F. Diagnosis, Treatment, and Monitoring of Patients With Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y). 2016 Sep;12(9):561-564.
  8. Poordad F. Treatment of Hepatitis C Virus Genotype 3 Infection. Gastroenterol Hepatol (N Y). 2015;11(10):715-7.
  9. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016. pii: S0016-5085(16)34816-8.
  10. Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J. High Antiviral Activity of NS5A Inhibitor ABT-530 With Paritaprevir/Ritonavir and Ribavirin Against Hepatitis C Virus Genotype 3 Infection. Liver Int. 2016 Jan 18. doi: 10.1111/liv.13067. [Epub ahead of print]
  11. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446. [Epub ahead of print]
  12. Poordad F. Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician. Clin Liver Dis. 2015;19(4):ix-x
  13. Poordad F, Rustgi V, Brown RS Jr, Patel V, Kugelmas M, Regenstein F, Balart L, LaBrecque D, Brown K, Avila M, Biederman M, Freed G, Smith R, Bernstein M, Arnold H, Cahan J, Fink S, Katkov W, Massoumi H, Harrison S. The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). Therap Adv Gastroenterol. 2015;8(5):263-9.
  14. Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Int. 2015;35(11):2358-62.
  15. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313(17):1728-35.
  16. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313(17):1736-44.
  17. Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015:1-27.
  18. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low Relapse Rate Leads to High Concordance of SVR12 with SVR24 After Treatment with ABT-450/r, Ombitasvir, Dasabuvir Plus Ribavirin in Subjects with Chronic HCV Genotype 1 Infection in the AVIATOR Study. Clin Infect Dis. Clin Infect Dis. 2015;60(4):608-10
  19. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769-75
  20. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Silva-Tillmann BD, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med. 2014;370(21):1973-82.
  21. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-32
  22. Lawitz E, Poordad FF, Pang P, Hyland R, Ding X, Mo H, Symonds W, McHutchison J, Membreno F. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-23.
  23. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson D, Rossaro L, Balart L, Morgan T, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 2013;145(5):1035-1044.
  24. Poordad F, Lawitz E, Kowdley K, Cohen D, Podsacki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. N Engl J Med 2013;368:45-53
  25. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Gastroenterology. 2012;143(3):608-618.
  26. Poordad F; McCone J; Bacon B; Bruno S; Manns M; Sulkowski M; Jacobson I; Reddy R; Boparai N; Sniukien V; Brass C; Albrecht JK; Bronowicki JP for the Sprint 2 Investigators. Boceprevir with Peginterferon and Ribavirin for Chronic Hepatitis C. N Engl J Med. 2011;364:1195-1206.
  27. Poordad F, Theodore D, Sullivan J, Grotzinger K. Medical Resource Utilization and Healthcare Costs in Patients with Chronic Hepatitis C Viral Infection and Thrombocytopenia. J Med Econ. 2011;14(2):194-206

Book Chapters

  1. Poordad FF. Evaluation of Abnormal Liver Enzymes and the Role of Liver Biopsy. Advanced Therapy of Gastroenterology and Liver Disease, 5th Edition.; 604-610.
  2. Poordad FF. Chronic Hepaititis C Infection: Factors Promoting Progression of Disease. Schiff’s Diseases of The Liver, 9th Edition
  3. Chee GM, Poordad FF. Hbv therapy following unsuccessful interferon therapy: how do you see the role for oral therapies? Clinical Dilemmas in Viral Liver Disease, 1st Edition, 2010, Blackwell Publishing
  4. Poordad F, Chee GM. Pharmacology and mechanisms of action of antiviral drugs: Ribavirin analogues. Advanced Therapy for Hepatitis C Infection. 2010, Wiley-Blackwell
  5. Clinics in Liver Disease, A New Era in Hepatitis C. Edited by Poordad, F. 2011
  6. Primary Liver Cancer, Hepatocellular Carcinoma. Edited by Reau N and Poordad F. 2012 Humana Press

Kermit V. Speeg, MD

Abstract

  1. Nguyen NTT, Ha CP, Harring TR, Chu D, Kar B, O‘Mahony C, Bakaeen F, Washburn WK, Halff GA, Goss JA, Speeg KV,. Dilated Cardiomyopathy after Orthotopic Liver Transplantation: A Multi-Institution Report of Six Cases Treated with Mechanical Assist Devices 2011 Jan. (Hepatology; vol. 54, no. 661).
  2. Lytvak I, Prihoda TJ,Speeg KV, Washburn WK, Halff GA, Sharkey FE. Microsteatosis More Significant Than Macrosteatosis in Predicting Early Post Transplant Hepatic Non-Function 2010 Mar. (Modern Pathology; vol. 23, no. 364A).
  3. Cura M, El-Merhi F, SURI R, Lopera JE, Speeg KV, Guerrero JA, Washburn WK, Halff GA. Transplant free survival (TFS) after Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation with the Viatorr covered-stent. 2010. (Cardiovascular and Interventional Radiological Society of Europe).
  4. Cura M, Speeg KV, El-Merhi F, SURI R, Lopera JE, Washburn WK, Halff GA. Transjugular intrahepatic portosystemic shunts (TIPS) creation in recurrent hepatitis C (HCV) cirrhosis after Liver Transplantation (LT). 2010. (Cardiovascular and Interventional Radiology Society of Europe).
  5. Dwivedi S, Berg MW, Eidem M, Speeg KV, Guerrero JA, Nazario H, Patel S. Endoscopic Ultrasound-Guided Pericardiocentesis in a Patient With Disseminated Cryptococcus Infection 2009 Apr. p. S240. (Gastrointestinal Endoscopy; vol. 69, no. 2).
  6. Hall RC, Speeg KV, Riley DJ, Gister C, Maxwell PR. Evaluation of risk factors for central pontine myelinolysis after liver transplantation. 2009. (Poster at American Transplant Congress).
  7. Hall RC, Maxwell PR, Speeg KV, Green BK, Lewis J. Predictors of Outcomes in Hepatitis C-Related Liver Transplants: How are we doing? Dallas, Texas: 2008 Apr. (proceedings from Alcalde Regional Residency Leadership Conference).
  8. Guerrero JA, Speeg KV. HCV Ab Negative HCV Infection in a Kidney Transplant 2005 Oct. (American Journal of Gastroenterology).
  9. Washburn WK, Nichols, L, Mejia A, Speeg KV, Halff GA. Recipient MELD Score and Resource Utilization: Higher is Higher. Presented at the American Transplant Congress, Seattle, WA: 2005 May. p. 425. (American Journal of Transplantation; vol. 5, no. s11).
  10. Guerrero J, Speeg KV. HCV-Ab negative HCV infection in a kidney transplant recipient. Poster at the American College of Gastroenterology. 2005: 2005 May.
  11. Pollack MS, Speeg KV, Callander NS, Freytes CO, Halff GA. Severe graft versus host disease manifesting eight months after liver transplantation 2004. p. S63-S63. (Human Immunology; vol. 65).
  12. Washburn WK, Speeg KV, Guerrero JA, Havranek R, Esterl RM, Abrahamian GA, Cigarroa FG, Halff GA. MELD: Impact of Hepatocellular Carcinoma on the Adult Liver Transplant Waiting List 2003. p. 374A. (Hepatology; vol. 38).
  13. Pollack MS, Speeg KV, Nolan III CR, Washburn WK, Esterl RM, Abrahamian GA, Halff GA. Successful Combined Liver/Kidney Transplantation in Highly Sensitized, Crossmatch Positive Patients. 2002 Oct. p. S74. (Human Immunology; vol. 63, no. 10).
  14. Pollack MS, Havranek, R, Halff GA, Esterl RM, Washburn WK, Cigarroa FG, Speeg KV. Liver Transplant Recipients with Positive T-cell Cross-matches Have Excess Mortality. 2000 Oct. p. s91-s91. (Human Immunology; vol. 61, no. Sup 2).
  15. Washburn WK, Speeg KV, Esterl RM, Tourtellot C, Pollack MS, Halff GA. Liver Transplantation Using Minimal Steroids, Prograf, Cellcept, and Daclizumab. 2000. p.S166-S166. (Transplantation; vol. 69, no. 8).
  16. Speeg KV, Gross GW. Effects of cholestasis on cimetidine sulfoxidation. 1990 Apr.p. A635. (Gastroenterology; vol. 98).

Book Chapter

  1. Espinoza A, Speeg KV, Washburn K, Halff G. Liver Transplantation In: Espinoza A, Speeg, Washburn K, Halff G. Essential Emergency Medicine for the Healthcare Practitioner. Saunders-Elsevier; 2007.
  2. Speeg KV, Halff GA, Schenker S. Metabolism of drugs before and after liver transplantation. In: Maddrey WC, Schiff E, Sorrell MF. Transplantation of the Liver, 3rd Ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
  3. Speeg KV, Bay MK. Prevention and Treatment of Drug-Induced Liver Disease In: Lewis J.H.. Gastroenterology Clinics of North America. Philadelphia: W.B. Saunders; 1995.

Editorial

  1. Schenker S, Speeg KV. The Risk of Alcohol Intake in Men and Women: All May Not Be Equal! N Engl J Med 1990;322:127-129.
  2. Schenker S, Desmond PV, Speeg KV, Hoyumpa AM. Cryptic nature of bromacriptine therapy in portal systemic encephalopathy. Gastroenterology 1980 May;78(5Pt1):1094-1097.

Journal Article

  1. Lee SM, Speeg KV, Pollack MS, Sharkey FA. Progression of morphologic changes after transplantation of a liver with heterozyzous alpha-1 antitrypsin deficiency Human Pathology 2012;43:753-756.
  2. Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA.. High-grade Microsteatosis and Delay in Hepatic Function after Orthotopic Liver Transplantation Human Pathology 2011:1337-1342.
  3. Cura MA. Postoak D. Speeg KV. Vasan R.. Transjugular Intrahepatic Portosystemic Shunt for Variceal Hemorrhage due to Recurrence of Hereditary Hemorrhagic Telangiectasia in a Liver Transplant Journal of Vascular and Interventional Radiology 2010;21:135-139.
  4. Wang Y, Speeg KV, Washburn WK, Halff G.. Sirolimus plus Sorafenib in Treating a Patient with HCC Recuurence Post-Liver Transplantaion. World Journal of Gastroenterology 2010:5518-5522.
  5. Washburn WK, Pollock BH, Nichols L, Speeg KV, Halff G. Impact of recipient MELD score on resource utilization. Am J Transplant 2006 Oct;6(10):2449-2454.
  6. Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA. Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol 2005 Jan;66(1):28-31.
  7. Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004 Apr;231 (1):231-236.
  8. Lovell MO, Speeg KV, Havranek RD, Sharkey FE. Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine. Hum Pathol 2003 Feb;34(2):187-189.
  9. Baughman SM, Speeg KV. Use of orthopedic traction device for Sengstaken- Blakemore counter-traction. Contemp Surg 2003;59:378.
  10. Rettally CA, Speeg KV. Infection with Listeria monocytogenes following orthotopic liver transplantation: Case report and review of the literature. Liver Tranplant Proc 2003;35:1485-1487.
  11. Ferral H, Vasan R, Speeg KV, Serna S, Young C, Postoak DW, Wholey MH, McMahan CA. Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol 2002 Nov;13(11):1103-1108.
  12. Postoak DW, Ferral H, Washburn WK, Speeg KV, Wholey MH. Transjugular intrahepatic portosystemic shunt creation in a patient with situs inversus. J Vasc Interv Radiol 2002 Jul;13(7):755-756.
  13. Mejia A, Halff GA, Esterl R, Cigarroa F, Speeg KV, Villarreal R, Washburn K. Outcome of Liver Transplantation in Hispanics versus Non-Hispanics: Is There a Difference? Transplant Proc 2002 Jun;34(4):1236-1238.
  14. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G. Steroid Elimination 24 hours After Liver Transplantation Using Daclizumab, Tacrolimus, and Mycophenolate Mofetil. Transplantation 2001 Nov;72(10):1675- 1679.
  15. Schenker S, Speeg KV, Perez A, Finch J. The effects of food restriction in man on hepatic metabolism of acetaminophen. Clin Nutr 2001 Apr;20(2):145-150.
  16. Patterson JE, Peters J, Calhoon JH, Levine S, Anzueto A, Al-Abdely H, Sanchez R, Patterson TF, Rech M, Jorgensen JH, Rinaldi MG, Sako E, Johnson S, Speeg V, Halff GA, Trinkle JK. Investigation and Control of Aspergillosis and Other Filamentous Fungal Infections in Solid Organ Transplant Recipients Transpl Infect Dis 2000 Mar;2(1):22-28.
  17. St Laurent M, Esterl RM, Halff GA, Speeg KV. Gallbladder Carcinoma Producing Alpha-fetoprotein. J Clin Gastroenterol 1999 Mar;28(2):155-158.
  18. Barnes CJ, Hamby-Mason RL, Hardman WE, Cameron IL, Speeg KV, Lee M. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomark Prevent 1999;8:311-315.
  19. Cai TH, Esterl RM, Nichols L, Cigarroa F, Speeg KV, Halff GA. Improved Immunosuppression with Combination Tacrolimus (FK506) and Mycophenolic Acid in Orthotopic Liver Transplantation. Transplant Proc 1998 Jun;30(4):1413-1416.
  20. Lahiri SA, Halff GA, Speeg KV, Esterl RM. Indium-111 WBC Scan Localizes Infected Hepatic Cysts and Confirms Their Complete Resection in Adult Polycystic Disease. Clin Nucl Med 1998;23(1):33-34.
  21. Esterl RM, St Laurent M, Bay MK, Speeg KV, Halff GA. Stent Migration and Small Bowel Perforation After Endoscopic Biliary Stent Placement in a Liver Transplant Recipient. J Clin Gastroenterol 1997 Mar;24(2):106-110.
  22. Hardman WE, Cameron IL, Beer WH, Speeg KV, Kadakia SC, Lang KA. Transforming growth factor a Distribution in rectal crypts as a biomarker of decreased colon cancer risk in patients consuming cellulose. Cancer Epidemiology, Biomarkers and Prevention 1997;6:633-637.
  23. Halff GA, Esterl RM, Speeg KV. The Use of Cellcept to Minimize Prograf Toxicity in Early Post-operative Liver Transplant Patients with Renal Insufficiency. J Hepatology 1996;25:203-203.
  24. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology 1991;14:1013-1015.
  25. Leighton J, Bay MK, Maldonado AL, Johnson RF, Schenker S, Speeg KV. The effect of liver dysfunction on colchicine pharmacokinetics in the rat. Hepatology 1990;11:210-215.
  26. Meredith CG, Muhoberac BB, Gray JP, Speeg KV, Dunn D, Hoyumpa AM, Schenker S. Hepatic oxidative drug metabolism and the microsomal mileau in a rat model of congenital hyperbilirubinemia. Biochem Pharmacol 1986 Nov;35(21):3831-3837.
  27. Nelson DC, Avant GR, Speeg KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology 1985 Mar;5(2):305-309.
  28. Mitchell M, Schenker S, Speeg KV Jr. Selective Inhibition of Acetaminophen Oxidation and Toxicity by Cimetidine and Other Histamine H2-Receptor Antagonists in vivo and in vitro in the Rat and in Man. J Clin Invest 1984;73:383-391.
  29. Speeg KV Jr, Patwardhan R, Avant R, Mitchell M, Schenker S. Inhibition of Microsomal Drug Metabolism by Histamine H2-Receptor Antagonists Studied in vivo and in vitro in Rodents. Gastroenteorlogy 1981;81:1052-1060.
  30. Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg KV Jr. Lack of Tolerance and Rapid Recovery of Cimetidine Inhibited Chlordiazepoxide (Librium) Elimination. Gastroenterology 1981;81:547-552.
  31. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV Jr. Cimetidine Spares the Glucuronidation of Lorazepam and Oxazepam. Gastroenterology 1980;79:912-916.
  32. Lopera JE, Speeg KV, Garg D, Michalek J, Kroma G, Suri R, Castaneda-Zuniga W.. Effect of Liver Volume in Morbidity and Mortality after elective TIPS
  33. Poordad F, Lawitz E, Gutierrez J, Guerrero J, Speeg KV, Swenson ES.. An HCV Positive Recipient of an HCV-Postive Donor Liver Successfully treated Before and Immediately After Liver Transplantation with Daclatasvir, Sofosbuvir and Ribavirin American J Transplantation.

Jennifer T. Wells

  1. Wells JT, Lucey MR, Said A. Hepatitis C in Transplant Recipients of Solid Organs, Other than Liver. Clinics and Liver Disease. 2006 Nov 10(4):901-17.
  2. Wells JT, Agni R, Said A, Dureja P, Tome S, Lucey MR. The Impact of Acute Alcoholic Hepatitis in the Explanted Recipient Liver on Outcome after Liver Transplantation. Transplantation Dec 2007.
  3. Tome, Santiago, Wells, JT, Said, Adnan, Lucey, ML. Quality of life after liver transplantation. A systematic review. Journal of Hepatology. April 2008.
  4. Wells JT, Runo JR, Lucey ML. Portopulmonary Hypertension in Liver Transplant Recipients. Editorial. Hepatology 2008.
  5. Said A, Wells JT. Management of hepatocellular carcinoma. Minerva Med. 2009 Feb;100(1):51-68.
  6. Landaverde, Carmen, Wells, JT, Gutierrez, J, Poordad, F. Treatment of patients with HCV genotype 3: Where are we now? Clinical Liver Disease. Volume 6, Issue 4. Oct 2015:79-81.
  7. Wells, JT, Landaverde, Carmen, Gutierrez, J, Lawitz, Eric. Management of Patients with HCV resistance-associated variants to NS5A inhibitors: Where are we now? Clinical Liver Disease. Volume 6, Issue 4. Oct 2015:82-85.
  8. Landaverde, Carmen, Wells, Jennifer, Hamner, Rebekah, Goldstein, Janie. Dual Therapy of grazoprevir and elbasvir for the treatment of HCV. Expert Review of Gastroenterology & Hepatology. Online Jan 2016.
  9. Book Chapters

  10. Said A, Safdar N, Wells JT, Lucey MR. Liver Disease in Renal Transplant Patients. Book Chapter. Kidney Transplantation: Principles and Practices. 6th Edition. Editor Sir Peter J Morris, Stuart Knechtle.
  11. Said A, Wells, JT. The Epidemiology of Liver Disease. Book Chapter, Epidemiology of Chronic Diseases.
  12. Wells JT, Lucey MR. Transplant Medicine. Kumar & Clark’s Clinical Medicine. Elsevier.
  13. Wells JT, Lucey MR. Alcoholic Liver Disease. Book chapter for 2nd edition of the Textbook of Clinical Gastroenterology and Hepatology. Wiley-Blackwell.
  14. Perrillo, R, Wells JT. Hepatitis B. Sleisenger & Fordtran,10th edition.